August 4, 2022 11:10 AM EDT

FDA delays PDUFA date for Libtayo lung cancer combo; Swedish biotech hit flunks PhIII for chemo-enhancing drug

Lei Lei Wu

News Reporter

During its earnings call yesterday, Regeneron said that the FDA has delayed its decision on Libtayo in combination with chemotherapy in advanced non-small cell lung …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA delays PDUFA date for Libtayo lung cancer combo; Swedish biotech hit flunks PhIII for chemo-enhancing drug

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA de­lays PDU­FA date for Lib­tayo lung can­cer com­bo; Swedish biotech hit flunks PhI­II for chemo-en­hanc­ing drug

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA delays PDUFA date for Libtayo lung cancer combo; Swedish biotech hit flunks PhIII for chemo-enhancing drug